Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200...